



Atreca to Participate in Immuno-Oncology Panel at the 2018 BIO CEO & Investor Conference

REDWOOD CITY, Calif. -- February 8, 2018 -- Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today that Tito A. Serafini, Ph. D., Chief Executive Officer and Co-Founder, will participate in a [panel discussion on immuno-oncology](#) being held during the 2018 BIO CEO & Investor Conference on Monday, February 12, 2018, from 9:00 AM to 10:15 AM ET in New York, NY.

The panel, titled “Immuno-Oncology Milestone’s to Come: Pipelines Beyond CAR-T 1.0”, will take place at the New York Marriott Marquis.

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® technology profiles a patient’s immune response at the single-cell level at very high throughput essentially without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates designed to engage the human immune response in oncology and other indications, thus driving better therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.

Atreca’s technology provides unbiased and virtually error-free antibody and T cell receptor (TCR) sequences at from single B and T cells of active human immune responses, enabling the identification, generation, and analysis of functional human antibodies and TCRs directly from such responses

Contacts

Atreca, Inc.
Susan Berland

EVP and Chief Financial Officer

info@atreca.com

or

Media:

Justin Jackson, 212-213-0006, ext. 327

jjackson@burnsmc.com

or

Investors:

John Grimaldi, 212-213-0006, ext. 362

jgrimaldi@burnsmc.com

Source: Atreca, Inc.